Boston, MA (PRWEB) May 20, 2021 Leading off the morning’s presentations in MarketsandMarkets’ Virtual 5th Annual Bioprocessing of Biotherapeutics – UK, EU
Asymmetrex Discusses a Near Horizon for Stem Cell Dosage in Stem Cell Therapy and Gene Therapy Clinical Trial Supply Chains
Share Article
Today, May 11, in the Clinical Trial Supply USA 2021 – Virtual Conference, the President and CEO of stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., discussed new developments on the horizon for the supply chains for stem cell therapy and gene therapy clinical trials. In particular, he suggested that it is inevitable that regulatory agencies like the FDA and clinical trial sponsors will eventually require stem cell dosage data for all supply chain activities, as well as for stem cell treatments.
Share this article
CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/
Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, today announced the appointment of Tim Clackson, Ph.D., as Chief Executive Officer and as a member of the Company s Board of Directors. He succeeds interim CEO Iain Dukes, D.Phil., Theseus Co-Founder and OrbiMed Venture Partner, who will serve as Theseus Executive Chairman. I am thrilled to join the team of R&D leaders at Theseus, who have a proven track record and share my passion for oncology innovation, motivated by our direct experience helping change patients lives with targeted therapies, said Dr. Clackson. Collectively, we are leveraging decades of insight to develop innovative medicines to confront the scourge of treatment resistance. With the backing of our top-tier investors, I look forward to realizing Theseus vision to build an industry leading precisi